后细胞因子时代肾细胞癌转移灶完全切除术的生存获益
该研究基于单中心肾切除登记库,纳入2006至2017年间首次出现转移的586例单侧散发性肾细胞癌患者,其中158例接受完全转移灶切除术。中位随访3.9年,完全转移灶切除组2年肿瘤特异性生存率显著高于未切除组(84% vs 54%,p<0.001),校正后与肾癌死亡风险显著降低相关(HR 0.47,95%CI 0.34-0.65,p<0.001)。
要点
- 完全转移灶切除与肾癌特异性生存改善相关(HR 0.47,95%CI 0.34-0.65)
- 93%完全转移灶切除患者未接受针对首发转移灶的全身治疗
- 是否手术需在充分共同决策后于合适患者中考虑
核心结论
- 在靶向治疗与检查点阻断可及的后细胞因子时代,肾细胞癌转移灶完全手术切除与肿瘤特异性生存改善相关。
- 完全转移灶切除可在经过共同决策程序的合适患者中考虑。
研究设计与样本
- 单中心肾切除登记库回顾性队列研究,纳入2006至2017年间首次出现转移的586例单侧散发性肾细胞癌肾切除患者。
- 其中158例接受完全转移灶切除术,采用Cox比例风险模型评估其与肿瘤特异性生存及总生存的关联。
主要发现
- 转移诊断后中位随访3.9年,期间403例死亡,其中345例死于肾细胞癌。
- 完全转移灶切除组147例(93%)未接受针对首发转移灶的任何全身治疗。
- 完全转移灶切除组与未切除组的2年肿瘤特异性生存率分别为84%与54%(p<0.001)。
- 校正年龄、性别及转移时间、数量与部位后,完全转移灶切除与肾癌死亡风险显著降低相关(HR 0.47,95%CI 0.34-0.65,p<0.001)。
关键数值与推荐
- 完全转移灶切除组2年肿瘤特异性生存率84%,未切除组54%,p<0.001。
- 校正后完全转移灶切除与肾癌死亡风险降低相关,HR 0.47(95%CI 0.34-0.65,p<0.001)。
- 完全转移灶切除组中93%(147例)未接受首发转移灶的全身治疗。
临床怎么用
- 对后细胞因子时代适合的患者,完全切除转移灶可作为改善肿瘤特异性生存的候选策略。
- 实施前应与患者充分共同决策,结合年龄、转移时间、数量与部位等风险因素个体化评估。
局限性
- 为单中心回顾性登记库研究,存在选择偏倚可能。
- 未报告完全转移灶切除组与未切除组在全身治疗暴露上的详细比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Data supporting complete metastasectomy of metastatic renal cell carcinoma were derived primarily from the era of cytokine therapy. Whether complete metastasectomy remains beneficial in patients who receive more recently approved systemic therapies has not been well studied. The objective of this study was to examine survival outcomes among patients treated with complete metastasectomy in the era of targeted therapy and checkpoint blockade availability. MATERIALS AND METHODS: We queried our institutional nephrectomy registry and identified 586 patients who underwent partial or radical nephrectomy of unilateral, sporadic renal cell carcinoma with a first occurrence of metastasis between 2006 and 2017. Of these patients 158 were treated with complete metastasectomy. Associations of complete metastasectomy with cancer specific and overall survival were assessed using Cox proportional hazards models. RESULTS: Median followup after the diagnosis of metastasis was 3.9 years, during which 403 patients died, including 345 of renal cell carcinoma. Of the patients treated with complete metastasectomy 147 (93%) did not receive any systemic treatment of the index metastatic lesion(s). Two-year cancer specific survival was significantly greater in patients with vs without complete metastasectomy (84% vs 54%, p <0.001). After adjusting for age, gender, and the timing, number and location of metastases complete metastasectomy was associated with a significantly reduced likelihood of death from renal cell carcinoma (HR 0.47, 95% CI 0.34-0.65, p <0.001). CONCLUSIONS: Complete surgical resection of metastases of renal cell carcinoma was associated with improved cancer specific survival in the post-cytokine era. It may be considered in appropriate patients after a process of shared decision making.
引用
- Lyon TD, Thompson RH, Shah PH, et al. Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era. J Urol. 2019. PMID: 31393812. doi:10.1097/JU.0000000000000488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。